OKYO Pharma Q4 2026 Earnings Report

OKYO Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

OKYO Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

OKYO Pharma Announcement Details

• Quarter: Q4 2026
• Date: 8/10/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

OKYO Pharma (NASDAQ:OKYO) Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease. The company’s second program, OK-202, is advancing in preclinical studies for chronic graft-versus-host disease, with plans to expand into other fibrotic indications. These programs leverage the company’s expertise in biologics engineering to deliver enhanced therapeutic profiles, including improved half-life and tissue targeting.

Founded through a combination of biotechnology collaborations and strategic financing, Okyo Pharma completed its initial public offering on the NASDAQ under the ticker symbol OKYO. Headquartered in the United States, the company has established research partnerships across North America and Europe to support its clinical development efforts. Leadership is headed by Chief Executive Officer Thomas Baum, Ph.D., who brings extensive experience in biologics development and regulatory strategy.